{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:47:04Z","timestamp":1791121624343,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ctrv.2013.09.004","type":"journal-article","created":{"date-parts":[[2013,9,17]],"date-time":"2013-09-17T20:02:25Z","timestamp":1379448145000},"page":"285-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: A network meta-analysis"],"prefix":"10.1016","volume":"40","author":[{"given":"James","family":"Signorovitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Ayyagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Reichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Q.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2013.09.004_b0005","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.004_b0010","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.09.004_b0015","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.09.004_b0020","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.09.004_b0025","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.09.004_b0030","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.09.004_b0035","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.004_b0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"Wei","year":"2010","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2013.09.004_b0045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.leukres.2011.09.018","article-title":"What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?","volume":"36","author":"Deininger","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2013.09.004_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ctrv.2013.09.004_b0055","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.004_b0060","series-title":"Results of a Phase II Trial of Dasatinib as Frontline Therapy for Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)","author":"Pemmaraju","year":"2011"},{"key":"10.1016\/j.ctrv.2013.09.004_b0065","unstructured":"National Institute for Clinical Excellence. Guide to the methods of technology appraisal. NICE 2008 June: 1\u201380, <http:\/\/www.nice.org.uk\/media\/B52\/A7\/TAMethodsGuideUpdatedJune2008.pdf>; 2013 [accessed 14.01.2013]."},{"key":"10.1016\/j.ctrv.2013.09.004_b0070","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.ctrv.2013.09.004_b0075","unstructured":"Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. CADTH, p. 1\u201375, <http:\/\/www.cadth.ca\/media\/pdf\/186_EconomicGuidelines_e.pdf>; 2013 [accessed 14.01.2013]."},{"key":"10.1016\/j.ctrv.2013.09.004_b0080","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","article-title":"A randomized trial of dasatinib 100mg versus imatinib 400mg in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"120","author":"Radich","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.09.004_b0085","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1185\/03007995.2011.576238","article-title":"Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials","volume":"27","author":"Signorovitch","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ctrv.2013.09.004_b0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2162-3619-2-5","article-title":"The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis","volume":"2","author":"Mealing","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.ctrv.2013.09.004_b0095","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1158\/1078-0432.CCR-10-2922","article-title":"Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy","volume":"17","author":"Kantarjian","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.ctrv.2013.09.004_b0100","article-title":"Dasatinib compared to imatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): twelve-month efficacy and safety from the phase III DASISION study","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.004_b0105","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ctrv.2013.09.004_b0110","unstructured":"NICE DSU Technical Support Document 2. A general linear modelling framework for pair-wise and network meta-analysis of randomised controlled trials. <http:\/\/www.nicedsu.org.uk\/TSD2%20General%20meta%20analysis.final.08.05.12.pdf>; 2011 [accessed 31.01.2013]."},{"key":"10.1016\/j.ctrv.2013.09.004_b0115","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1063\/1.1699114","article-title":"Equation of state calculations by fast computing machines","volume":"21","author":"Metropolis","year":"1953","journal-title":"J Chem Phys"},{"key":"10.1016\/j.ctrv.2013.09.004_b0120","unstructured":"R Core Team. R: a language and environment for statistical computing. R: foundation for statistical computing. <http:\/\/www.R-project.org\/>; 2012."},{"key":"10.1016\/j.ctrv.2013.09.004_b0125","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 4.2013."},{"key":"10.1016\/j.ctrv.2013.09.004_b0130","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1158\/1078-0432.CCR-05-2574","article-title":"Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients","volume":"12","author":"Iacobucci","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.09.004_b0135","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800mg\/d versus 400mg\/d versus 400mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.004_b0140","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-08-1195","article-title":"Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response","volume":"15","author":"Palandri","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.09.004_b0145","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2013.09.004_b0150","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00277-012-1650-8","article-title":"Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"92","author":"Oyekunle","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2013.09.004_b0155","unstructured":"NICE DSU Technical Support Document 3: Heterogeneity. Subgroups, meta-regression, bias, and bias-adjustment. <http:\/\/www.nicedsu.org.uk\/TSD2%20General%20meta%20analysis.final.08.05.12.pdf>; 2011 [accessed 31.01.2013]."},{"key":"10.1016\/j.ctrv.2013.09.004_b0160","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1467-985X.2010.00639.x","article-title":"Estimation and adjustment of bias in randomized evidence by using mixed treatment comparison meta-analysis","volume":"173","author":"Dias","year":"2010","journal-title":"J R Stat Soc: A"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721300193X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721300193X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T01:20:42Z","timestamp":1539393642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573721300193X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S030573721300193X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.09.004","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}